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A B S T R A C T
Preeclampsia is a serious vascular complication of the human pregnancy, whose etiology is still poorly under-
stood. In preeclampsia, exacerbated apoptosis and fragmentation of the placental tissue occurs due to devel-
opmental qualities of the placental trophoblast cells and/or mechanical and oxidative distress to the syncytio-
trophoblast, which lines the placental villi. Dysregulation of the complement system is recognized as one of the
mechanisms of the disease pathology. Complement has the ability to promote inflammation and facilitate
phagocytosis of placenta-derived particles and apoptotic cells by macrophages. In preeclampsia, an overload of
placental cell damage or dysregulated complement system may lead to insufficient clearance of apoptotic par-
ticles and placenta-derived debris. Excess placental damage may lead to sequestration of microparticles, such as
placental vesicles, to capillaries in the glomeruli of the kidney and other vulnerable tissues. This phenomenon
could contribute to the manifestations of typical diagnostic symptoms of preeclampsia: proteinuria and new-
onset hypertension. In this review we propose that the complement system may serve as a regulator of the
complex tolerance and clearance processes that are fundamental in healthy pregnancy. It is therefore re-
commended that further research be conducted to elucidate the interactions between components of the com-
plement system and immune responses in the context of complicated and healthy pregnancy.
1. Introduction
Preeclampsia is a life-threatening vascular complication of the
human pregnancy characterized by new-onset hypertension and pro-
teinuria or subjective symptoms during the second half of the preg-
nancy [1,2]. Preeclampsia affects 3–5% of pregnancies worldwide, but
the mechanisms underlying the disease remain elusive and no curative
treatment is available [3]. However, immunological mechanisms are
strongly indicated in the disease process [4]. Preeclampsia is initiated
in the early pregnancy, when the invading placental trophoblast cells
fail to complete the remodulation process of the maternal spiral uterine
arteries resulting in an aberrant high-volume, high-pressure circulatory
conditions in the intervillous space of the placental tissue [5–7]. Me-
chanical shear and turbulent blood flow cause injury to the syncytio-
trophoblast layer, the single fused cell barrier between the placental
tissue and maternal blood flow [8]. Concurrently, ischemic injury due
to pulsatile reperfusion may result in placental dysfunction and
impaired placental capacity [9–11]. As a result, the placental syncy-
tiotrophoblast disintegrates exposing the villi to components within the
maternal blood and resulting in an increased load of released placental
debris [12,13]. The placental microparticles enter the maternal circu-
lation and challenge both her innate and adaptive immune systems
[14,15]. As a consequence, the placental debris could activate the
complement and coagulation systems, cause microthrombi, endothelial
damage, and breakdown of the systemic maternal-fetal tolerance
[16–18].
The complement system is an integral part of innate immunity
consisting of more than forty factors that interact in a progressive
cascade to instigate terminal pathway activation. Complement activa-
tion may become initiated via any of three distinct pathways, the
classical, lectin, or the alternative pathway (Fig. 1). A step-wise enzy-
matic cleavage of the activating components will generate opsonizing
molecules to label targets for phagocytosis and anaphylatoxins that are
potent chemoattractants. The classical pathway (CP) is activated when
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the C1 complex binds to the target cell leading to activation of C4, C2
and formation of the C3/C5 convertase, which will activate C3 and
initiate activation of the terminal pathway (TP) [19]. C1q deposits di-
rectly on apoptotic cells, exposed cellular structures after damage, and
some microorganisms. It is also targeted via pattern recognition mole-
cules such as IgGs, IgM, and pentraxins (CRP and PTX-3) [20].
The lectin pathway (LP) of complement activation is analogous to
the CP. It is activated by mannose-binding lectin (MBL) or one of the
ficolins (ficolins 1, 2 and 3) binding to microbes that have certain oli-
gomeric sugars, such as mannose or N-acetylglucosamine or acetyl
groups (ficolins) on their surfaces. With the MBL-associated serine
protease enzymes, MASP1, MASP2, and MASP3, the lectins form com-
plement activating complexes. Activation of C4 and C2 leads to their
deposition and formation of the C3 convertase, C4b2a.
The alternative pathway (AP) is one of the most evolutionarily an-
cient method of self-nonself discrimination [21]. In AP activation, C3b
is covalently bound on cell surfaces and thereafter either inactivated by
soluble or surface-bound complement regulators. Failing inhibition, AP
activation becomes accelerated in the so-called amplification loop,
where C3bBb convertases will activate an expanding number of native
C3 molecules. The generated layer of C3b molecules opsonizes the
target and promotes its phagocytosis. AP activation will also lead to
activation of C5 and membrane attack complex (MAC) formation as a
result of TP activation. The surfaces missing protective regulatory
components leading to AP activation include fungi, viruses and certain
bacteria [19]. Nonviable endogenous cells, like apoptotic, ischemic, or
aged cells, can also become targets for AP attack, if they lose their
ability to protect against complement activation.
Complement regulating proteins are integral in protecting healthy
cells from destruction. Many of the complement inhibitors are com-
posed of small, approximately 60 amino-acid long units called com-
plement control protein (CCP) domains. These regulators are encoded
in a distinct gene cluster on chromosome 1, called regulators of com-
plement activation (RCA) [22]. Nevertheless, an optimal degree of
continuous small grade complement activation is maintained for sen-
sing and clearing away injured and dying cells and allowing robust
activation on invading microorganisms.
Complement activation can be regulated at the level of initiation,
amplification, and generation of effectors such as opsonins, MAC, and
proinflammatory anaphylatoxins. Complement regulators can function
in solution or on cell surfaces. Soluble inhibitors include C1 inhibitor
(C1INH), C4b binding protein (C4BP), factor H, clusterin, and
Fig. 1. Complement system can be activated via the al-
ternative pathway (green), classical pathway (yellow) or
the lectin pathway (blue). They all lead to activation of C3
and of the terminal pathway (orange) by formation of C3/
C5 convertases. The most important complement in-
hibitors are shown in bright red. Factor H (FH) and C4b
binding protein (C4BP) are the most important soluble
regulators of the early pathways of complement activa-
tion. FH is particularly important in the inactivation of
C3b, while C4BP is primarily active in the classical
pathway of complement activation. The triangular reg-
ulators are surface bound inhibitors. C5a and C3a are
potent anaphylatoxins with the capacity to recruite and
activate immune cells to the site of complement activa-
tion. MAC – membrane attack complex, CLU – clusterin,
VTN – vitronectin.
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vitronectin. C1INH controls the C1r, C1s, and the MASP serine esterase
enzymes in CP and LP (Fig. 1). The main soluble regulator of AP is C3
inhibitor factor H (FH). FH consists of 20 CCP domains with different
binding specificities for C3b in solution and, importantly, on cell sur-
faces through sialic acid/polyanion binding domains that stabilize the
FH-C3b interaction [22]. FH has a crucial function in acting as a co-
factor for factor I (FI) in inactivating C3b and in inhibiting the AP C3
convertase, C3bBb. C4BP has analogous functions in promoting in-
activation of C4b and controlling the CP C3 convertase, C4b2a. Clus-
terin and vitronectin act as soluble inhibitors of the TP by scavenging
intermediate soluble terminal complement complexes. The membrane-
bound regulators CD35, CD46 and CD55 regulate CP and AP of com-
plement activation, while CD59 prevents membrane attack against our
own cells.
Properdin is the only positive regulator of complement system,
acting partially in opposition to FH by stabilizing the AP C3-convertase
C3bBb [23]. By preventing membrane insertion of MAC, the TP in-
hibitors clusterin and vitronectin form a soluble C5b-9 complex that can
be used as a diagnostic marker for complement activation. Cells express
membrane proteins that protect from excessive complement activation.
CD35 (CR1) inhibits C3 activation and binds C3b- and C4b-coated
particles to promote their clearance [24]. CD46 (Membrane Cofactor
Protein, MCP) acts as a cofactor for FI thus promoting inactivation of
C4b and C3b, whereas CD55 (Decay Accelerating Factor, DAF) pro-
motes the disassembly of C3-convertases. CD59 (protectin, MAC-IP) is
the only MAC inhibitor on cell membranes, blocking the generation and
insertion of polymeric C9 complexes into cell membranes [25].
Severe disturbances in complement regulation can lead to such
catastrophic consequences as the atypical hemolytic uremic syndrome
(aHUS) and other forms of thrombotic microangiopathy (TMA) [26].
Central to these is complement attack against endogenous tissue
structures, endothelial cells, blood cells and platelets with a consequent
vascular damage and organ, notably kidney failure. Pregnancy is a well-
known potential trigger for such syndromes [27,28]. The underlying
reasons in aHUS are usually mutations in genes of complement com-
ponents that influence its function on surfaces (factor H, MCP, factor I,
C3, factor B, thrombomodulin). Most commonly, mutations are located
in the C-terminus of factor H. AHUS-related mutations in C3 and factor
B lead to their increased activity. Also, autoantibodies against factor H
predispose to aHUS.
In this review we explore the multiple interactions, roles, and effects
of complement system in the context of pregnancy and pathogenesis of
pregnancy complications with focus on preeclampsia.
2. Aberrant complement regulation in preeclamptic pregnancy
Complement belongs to the first line of defense in the circulation
and tissues. Extravillous trophoblast cells invading into maternal tissues
will potentially face complement activating antibodies within the ma-
ternal tissue. Therefore, they must be sufficiently protected from the
maternal complement system [29,30]. A second site in the need of
protection from complement activation is on the syncytiotrophoblast,
which is the placental surface that is constantly exposed to maternal
blood. Complement activation will result in the release of proin-
flammatory and chemotactic anaphylatoxins with the potential to cause
inflammation, vascular leakage and thrombosis. Insufficiently regulated
complement activation may also result in tissue damage characterized
by inflammatory lesions and increased apoptosis on the placental villi
[31–33]. Generation of the membrane attack complex will lead to
calcium influx into target cells, which in itself may cause a metabolic
storm, when sublytic C5b-9 induces apoptotic pathways and further
stresses the cells with unpredictable consequences. One of the con-
sequences is the release of vesicles in an attempt to remove the accu-
mulating MACs [34].
Complement has been studied in preeclampsia extensively
[30,35,36]. The larger body of evidence points towards an
overactivation of the maternal complement system in the disease [37].
Hypertensive disorders of pregnancy with impaired placental perfusion
have been proposed to result from excessive activation of the comple-
ment system causing inflammation or, alternatively, from deficiencies
in the system that compromise the proper development and perfusion of
the utero-placental unit [38]. Complement activation may occur
spontaneously, if control mechanisms are not sufficiently operational
[12]. An incompatibility between the maternal immune system and
placental cells may also include an imbalance of complement activation
and regulation. This can contribute to the pathogenesis of preeclampsia
[11]. In discordant cases, complement attack may compromise pla-
cental cells, if their protection fails. Alternatively, antibodies or exposed
tissue structures may act as the trigger.
C3 is the central component of complement system that has also
been the subject of several genetic studies in pregnancy complications.
Early work in mouse models demonstrated that the presence of C3 as
well as its appropriate regulation are prerequisites for a successful
pregnancy [39]. Current literature supports the hypothesis that re-
current miscarriages and preeclampsia may at least partially share
common immunological etiology [4,40]. Functional variants of the C3
gene have been described in idiopathic recurrent miscarriage patients
[41]. Furthermore, we found that the haplotype of C3 in a region that
codes for the binding domains of the protein associates to preeclampsia
risk in a sequence-specific manner [42]. C3 has also been found to be
upregulated both in the acute inflammation of the spiral arteries in
preeclamptic patients and in a hypertensive pregnant rat model [43].
Mutations in complement regulators have also been described in sys-
temic lupus erythematosus (SLE) patients with complicated pre-
eclampsia [44].
Factor H is the most potent regulator of the AP, with the capacity to
promote inactivation of complement C3b into the opsonin iC3b.
Opsonization by iC3b allows for phagocytosis of the target in the ab-
sence of full complement activation. Following exposure to active
complement, the placental villi are circumferentially protected from
complement attack by factor H deposition [45]. Factor H has also been
observed intracellularly in placental trophoblasts. Recently, in an un-
published study, we have observed a functionally defective maternal
factor H due to possibly de-novo genetic variants in seven cases of se-
vere/complicated preeclampsia. Factor H is known to have a non-
canonical immunomodulatory role independent of complement reg-
ulation. Factor H promotes the differentiation of inflammatory
monocyte-derived dendritic cells (DCs), whereby they are directed to-
wards a tolerogenic interleukin (IL)-10 and TGF- β dominated pheno-
type [46]. The possible tolerogenic role of factor H outside of com-
plement regulation has not been studied thus far in pregnancy. In
contrast to factor H, C4BP, the soluble regulator of the classical
pathway C3 convertase, is mostly deposited on apoptotic structures
such as placental knots [45]. Hereditary angioedema (HAE) is a disease
caused by the lack or insufficient function of C1-inhibitor. The effect of
pregnancy on the prevalence of HAE attacks is unpredictable and
variable [47]. Interestingly, while plasma levels of C1-inhibitor are
physiologically low during pregnancy, the levels are significantly lower
in preeclampsia in comparison to normal pregnancy, with lowest values
recorded in severe preeclampsia [48].
The amounts of circulating complement activation products are
elevated in early-onset severe preeclampsia and late-onset severe pre-
eclampsia [49]. Urine, but not plasma levels of soluble MAC (sC5b-9)
are elevated in preeclampsia [50]. This is likely a reflection of com-
plement-mediated damage of the kidney, which may result in the di-
agnostic sign of proteinuria. In preeclampsia, proteinuria has been at-
tributed to CP activation and linked to angiogenic dysregulation [51].
On the other hand, the mere proteinuria may result in the generation of
soluble terminal complexes in the proximal and distal tubuli of kidneys.
Studies in support of overactivation of the AP often report an excess of
factor B and its activation products Ba and Bb in the patient sera
[52,53]. However, the role of factor B is not clear [37]. A relative excess
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of C4d deposition on the placenta is observed in preeclamptic preg-
nancies in comparison to placentas from healthy pregnancies, where
C4d is mostly absent [54]. C4d is also observed in the endothelium of
kidney glomerular capillaries in preeclampsia [55]. The C4 protein pool
comprises two homologous C4 gene products. C4A preferentially binds
to proteins and C4B to carbohydrates. We have previously shown that
maternal heterozygous deficiencies of the C4A and C4B genes correlate
with severity of preeclampsia [45]. Specifically, in this small cohort,
C4A deficiencies were observed in 43% of early-onset preeclamptic
mothers in comparison to none observed in non-preeclamptic controls.
While homozygous C4A deficiencies are associated with autoimmune
diseases including SLE, homozygous C4B deficiencies are linked to in-
tolerance to sulphonamides and doxycycline as well to predisposition to
various infections by encapsulated bacteria and to post-infectious
symptoms [56].
Already in early immunohistochemistry studies C1q, C3 and C9
were seen in the preeclamptic placenta [57]. The syncytiotrophoblast of
early-onset preeclamptic placenta displays the highest amount of de-
posited C1q [45]. On the other hand, extravillous trophoblast cells of
placental origin express C1q, and first trimester cytotrophoblasts ex-
press components C3 and C4, of the complement system in an IFN-γ
driven process [58,59]. These findings, although interesting, remain
isolated observations. The role of the fetal complement system in pre-
eclampsia has not been studied thus far.
The TP of complement activation has a role in preeclampsia. In one
patient case, eculizumab, a monoclonal antibody inhibiting C5, was
used successfully for the treatment of severe preeclampsia and the he-
molysis, elevated liver enzymes, low platelets (HELLP) syndrome. Its
use resulted in improved laboratory values, as well as in the alleviation
of preeclampsia symptoms [60,61].
3. Complement in apoptosis and inflammation in preeclampsia
In the early stages of pregnancy, a certain amount of inflammation
is needed in order for the placentation process to succeed and lead to a
healthy pregnancy [62,63]. This is also reflected in complement acti-
vation, where soluble anaphylatoxins C3a and C5a are observed in in-
creased amounts during the healthy pregnancy [64]. In preeclampsia,
however, the inflammatory response is inflated. Apoptotic structures
and other injured tissue derived from the placenta and disrupted sys-
temic maternal endothelium increase the requirement for waste man-
agement and debris removal by phagocytosis [65,66]. Facilitating
phagocytosis is among the key roles of the complement system. In the
presence of the regulators (factor H, C4BP, MCP) the key activation
product C3b is inactivated by factor I into the opsonin iC3b, which is
the main ligand for complement receptors 3 and 4 (CR3 and CR4, re-
spectively). Complement receptors CR3 and CR4 are integrin-type re-
ceptors with signaling functions. They have an important role in the
clearance of apoptotic structures and other unwanted materials through
phagocytosis. Most apoptotic cells are cleared independently of com-
plement in the early stages of the apoptotic process. However, when the
number of apoptotic bodies increases, effective recognition of these
structures by complement has a crucial role in maintaining sufficient
clearance by phagocytosis [67]. We have recently discovered several
preeclampsia-related genetic variants within the genes coding for CR3
(ITGAM) and CR4 (ITGAX) with functional effects on the receptors’
interaction with iC3b. Excess burden or abnormal function of the
complement system may limit its capacity to perform the necessary
waste disposal function. Consequently, placental material cannot be
properly cleared, and accumulation may occur in maternal tissues, such
as in the lungs or blood vessels of kidneys causing inflammation and
vascular damage. Indeed, there is a growing body of evidence that
failure of the complement-facilitated phagocytosis of placental debris
and microthrombosis may contribute to the disease pathogenesis
(Fig. 2) [68–71]. Occlusion in the vascular capillaries could be due to
accumulation of microvesicles released from placenta or to a
disturbance in the regulation of the coagulation system [72]. Further-
more, antibodies, tissue degradation products or insufficient regulation
of complement activity may lead to complement overactivation with all
its inflammatory vascular consequences.
CR3 has been shown to have a dual role in regulating immune
system responses. Traditionally, it has been regarded as a pro-in-
flammatory receptor promoting innate immune-mediated inflamma-
tion. For example, it promotes the phagocytic uptake of particles and
phagocytosis-related cytotoxic functions especially in neutrophils
[73,74]. In monocytes, the engagement of CR3 or CR4 can lead to the
production of pro-inflammatory cytokines (IL-8, MIP1α, MIP1β, IL-1β)
[75,76]. In addition, CR3 interacts and supports the function of other
essential immune receptors such as CD14, Toll-like receptors (TLRs),
and FcRs [73]. In addition, the proinflammatory response (degranula-
tion, release of cytokines, and oxidizing compounds) related to pha-
gocytosis of serum-opsonized particles and phagocytosis-induced
apoptosis, was impaired in CR3-deficient mouse neutrophils [77]. This
observation emphasizes the inflammatory role of CR3 in these cells. In
addition to proinflammatory roles, CR3 also has a clear anti-in-
flammatory role in immunity, reviewed in [78]. CR3 (and the related
receptor CR4) are important for clearance of apoptotic cells, which is
associated with a reduced secretion of pro-inflammatory cytokines such
as IL-1, IL-6 and IL-12 [79]. The recognition of iC3b-opsonized apop-
totic cells leads to inhibition of pro-inflammatory NFκB signaling in
macrophages and dendritic cells [80]. Signaling through CR3 can also
suppress TLR responses [81–83]. Other outcomes of CR3 signaling in-
clude a decreased ability of dendritic cells to produce inflammatory
cytokines and dendritic cell -mediated suppression on activation of T-
cells, which both negatively regulate activation of the adaptive im-
munity [84–87].
Leukocyte-endothelial cell interaction is increased in preeclampsia.
This mechanism likely contributes to the increased infiltrate of
Fig. 2. Using complement receptors CR1, CR3, and CR4, antigen presenting
cells phagocytize placental particles that have been opsonized by complement
components such as C3b, recognized by CR1 or iC3b recognized by all three.
C1q is recognized by C1q receptors C1qR and C1qBP also expressed on antigen
presenting cells such as macrophages. In the normal system (black arrow) a
tolerogenic M2 response is induced. Due to mutations in complement receptors
or complement components, a dysfunctional complement activation (red ar-
rows) may result in impaired clearance. Inadequate clearance may also arise
due to complement hyperactivation and increased load of damage associated
molecular patterns (DAMPs) that is associated with preeclampsia. Inflammatory
M1 response can lead to further disruption of endothelial function disruption
and systemic consequences, including hypertension and proteinuria, which are
the diagnostic criteria in preeclampsia.
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neutrophils and mononuclear perivascular cells into the preeclamptic
placenta. The CR3 ligand, fibrinogen, which is related to tissue repair
has been shown also to affect signaling via the integrins, and enhance
the inflammatory response of the responding leukocytes [88].
In addition to phagocytic leukocytes, the subset of innate lymphoid
cells, natural killer (NK) –cells express CR3, which has been regarded as
a maturation marker on both mouse and human NK cells [89,90]. C3
fragments (C3a, iC3b) have shown to have a negative regulatory effect
on NK-cell activities (decreased production of IFN-γ, reduced ability for
direct and antibody-dependent tumor cell killing) [91,92]. In the first
trimester of pregnancy, the main decidual immune cells are uterine NK
cells with a CR3− (CD11b−) phenotype [93]. Besides their regulatory
role in placental development, the uterine NK cells have been shown to
promote the development of tolerogenic DCs and monocytes and sup-
press T helper type 17 (Th17)-mediated local inflammation [93,94]. To
conclude, CR3 appears to be a receptor, which regulates the nature of
the triggered immune response. The appropriate response depends
considerably on the type of the responding immune cell.
The structurally very similar CR4 appears to have overlapping
functions with CR3, and its specific role has been unclear for a long
time. Specific functions for CR4, i.e. tasks, which are more preferred by
CR4 than CR3, have just recently been elucidated. They suggest a di-
vision of labor between these two integrins [95]. These include a more
relevant role for CR4 than for CR3 in the regulation of macrophage
inflammatory functions [74].
In contrast to apoptosis, necrotic cell death may lead to an un-
controlled release of intracellular constituents into the extracellular
space. They can trigger the release of pro-inflammatory chemokines
and cytokines from immune cells that recognize the endogenous alarm
signals. Consequently, the immune system is further alarmed to recruit
a sufficient number of phagocytic cells to sites of injury to prevent the
spreading of infection or injury.
Obesity carries an increased risk for preeclampsia possibly due to
metabolic and/or immunological causes [96]. Adipose tissue may
harbor sterile inflammation, and it can be a source of complement ac-
tivation e.g. by actively producing the essential AP factor D (adipsin)
[97]. It has been shown that the chronic inflammation spanning from
the pregravidity phase of an obese mother bears consequences for the
pregnancy by an increase in the heterogeneous macrophage population.
This includes upregulation of CR3 in the placental macrophages [98],
which is also reflected in the activation of peripheral blood mono-
nuclear cells of the mother. A subset of macrophages identified by high
expression levels of CR4 is associated with increased lipid metabolism,
lipid antigen presentation and inflammation, while the macrophages
low in CR4 have a role in growth, remodeling and, maternal im-
munoregulation. The strongly CR4-expressing macrophages may reg-
ulate the decidual NK cell cytokine responses [99].
4. Complement receptors in preeclampsia and autoimmunity
The inability to handle apoptotic and necrotic waste is crucial in the
development of autoimmune disease, where the tolerance breaks down.
Insufficient CP activation and C1q deficiency have been shown to be
strongly involved in SLE, an immunoinflammatory disease considered
to result from an insufficient clearance of waste [100]. Some auto-
immune diseases, like SLE, tend to become worse during pregnancy,
possibly because of a greater challenge to the clearance system posed by
material derived from the placenta [101]. Interestingly, SLE shares
common features with the pregnancy complication preeclampsia, SLE
carries a 2- to 4- fold increased risk for preeclampsia during pregnancy
[96,102]. A polymorphism of ITGAM, which encodes the alpha subunit
of CR3, is associated with susceptibility to SLE [103,104]. The
rs1143679 ITGAM variant (encoding the R77H protein variant of CR3)
is considered as a major risk factor for the development of SLE. R77H
mutation leads to the reduction in CR3 functions in neutrophils, B cells,
and macrophages [105–107]. The R77H-substituted integrin receptor
was shown to adhere weakly to the complement factor iC3b and dis-
played reduced iC3b-dependent phagocytosis. In addition, the R77H-
CD11b variant was linked to increased levels in IL-6 production [108]
and increased type I interferon production in the context of SLE [109].
The evaluation of further risk variants in CR3 confirmed the reduced
ligand binding and reduced complement-mediated phagocytic capacity
of neutrophils carrying the mutant proteins [110]. This is in accordance
with the present knowledge, whereby the impaired clearance of dying
cells due to phagocytic defects has been implied in the pathogenesis of
SLE [111]. However, as CR3 plays many anti-inflammatory roles in
immune responses, it is clear that also immunological processes other
than clearance of apoptotic cells may be affected by the ITGAM variants
that are associated with SLE. The interaction between CR3 and iC3b-
opsonized apoptotic cells also leads to downregulation of the expression
of MHC class II antigens and costimulatory molecules in the phagocytic
cells [80]. This may serve to diminish the immune response following
phagocytosis of apoptotic cells.
SLE is an autoimmune disease, where pathogenic Th17-responses
have also been implicated [112,113]. A common complication of lupus
nephritis includes immune cell infiltration into the kidney. This may
result in tissue damage and onset of proteinuria [114]. Also in pre-
eclampsia, the Th17 cells have been shown to be the predominant T cell
population, while the number and function of Tregs is decreased [115].
Th17 cells are a distinct type of helper T cells, which are important in
protection against extracellular bacterial and fungal infections. In ad-
dition, they have been implicated in the pathogenesis of several auto-
immune diseases [116]. Since Th17 cells require cytokines (IL-1β, IL-6,
and IL-23) to differentiate and proliferate, the decreased secretion of
pro-inflammatory cytokines (cytokine skewing) from CR3-activated and
tolerogenic DCs may play a primary role in the suppression of patho-
genic Th17 responses [117]. In line with this, it was shown that mice
carrying CR3-deficient antigen presenting cells exhibited loss of per-
ipheral tolerance and increased Th17 cell numbers [118]. Furthermore,
it was shown that CR3 regulates the Treg/Th17 balance in murine
rheumatoid arthritis via interleukin-6 [119], while preeclampsia has
elsewhere been shown to predispose to rheumatoid arthritis [120]. It
was recently proposed that preeclampsia and rheumatoid arthritis share
the lack of transgenerational maternal-fetal microchimerism, i.e. ma-
terial passed on from previous pregnancies of the mother and grand-
mother, suggesting a shared mechanism of lacking possibly HLA-
mediated tolerogenic process in the two diseases [121]. CR3 is also
associated to negative regulation of B-cell receptor signaling to main-
tain autoreactive B cell tolerance [105]. Furthermore, B-cells lacking
the complement receptor 2 (CR2, CD21) have been found to be en-
riched in patients with autoimmune conditions such as SLE [122,123].
The role of CR2 as a receptor for C3d/C3dg and nuclear components
and as an activator of B-cells makes it as a potential candidate for in-
fluencing the pathogenesis of autoimmune diseases [124,125]. By being
the receptor for Epstein-Barr virus, CR2 may also promote polyclonal
auto-antibody responses [126].
Human complement receptor 1 (CR1, CD35) is widely expressed,
including erythrocytes, myeloid cells such as neutrophils and mono-
cytes, B-cells and also few T-cell populations [127]. CR1 expression is
observed in certain type of epithelial cells in the eye, skin and kidney.
In the latter, CR1 on glomerular epithelial cells has been shown to bind
immune complexes and protect the kidney glomeruli by regulating the
activity of complement. This suggests a role for CR1 in protecting the
kidney from complement-mediated damage [128]. CR1 mediates the
transport and promotes the phagocytosis of particles opsonized with
several complement-related proteins: C1q, C3b, C4b, MBL, and ficolin-
2. CR1 facilitates the clearance of pathogens and immune complexes
from the circulation [129–131]. The complement activity of CR1 in-
cludes acceleration of the decay of CP and AP C3 and C5 convertases
and co-factor activity for factor I -mediated cleavage of C3b/C4b to
iC3b/iC4b [132–135]. Reduced levels of CR1 and proteolytic cleavage
of CR1 are observed in patients with SLE [136]. Interestingly, reduced
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cell surface levels of CR1 correlate also with the severity of pre-
eclampsia symptoms [137]. A genetic variant resulting in a reduced
expression of CR1 was found to be associated with preeclampsia, being
even more common in the severe phenotype of HELLP syndrome [137].
Because of both the clearance and complement regulating activities,
CR1 function is among the most interesting candidates of preeclampsia
susceptibility.
5. Inflammation and angiogenic regulation in pathological
pregnancy
The interplay between vascular and endothelial disruption and in-
flammatory responses is complex [11]. CR1 variants are known to in-
fluence susceptibility also to placental malaria [138]. The persistence of
preeclampsia in the human population has been hypothesized to be
driven by selection pressure against placental malaria susceptibility
through immunological and vascular interactions. African-American
and certain Latin American populations have at least double the in-
cidence of preeclampsia, when compared to populations of European
origin [139,140]. In areas of Africa, where Plasmodium falciparum is
endemic, first pregnancies share a particular risk not only for pre-
eclampsia but also for placental malaria [141]. In a malaria endemic
region of Papua New Guinea in a cohort of pregnancies with high
parasitemia, a heterozygous genotype causing lower than regular ex-
pression of CR1 was associated with higher hemoglobin levels at birth
[142]. Also, an association to a low birthweight of infants was sug-
gested [142].
Soluble fms-like tyrosine kinase 1 (sFlt1 a.k.a. soluble vascular en-
dothelial growth factor receptor 1 sVEGFR1) is a soluble antagonist of
vascular endothelial growth factor (VEGF) and placental growth factor
(PIGF). Flt1 is expressed on inflammatory cells and endothelial cells
[143]. Interestingly, it has been shown that in placental malaria, the
fetal tissue will express an excess of sFlt1 apparently in an attempt to
regulate the maternal inflammatory response and thereby to reduce the
rate of spontaneous abortions [144].
In preeclampsia, an excess production of sFlt1 from placenta is
observed [145]. Consequently, maternal serum concentration of sFlt1
increases. Indeed, sFlt1 is one of the best biomarkers for preeclampsia.
During pregnancy, Flt1 is thought to limit vascular remodelling and
neovasculogenesis and to restrict placental growth [146]. Conse-
quently, positive selection of a genetic variant with capacity to resist
placental malaria may have influenced FLT1 allele frequencies within
the general population sufficiently enough to introduce a novel risk to
preeclampsia [147].
sFlt1 has also been implicated to have an anti-inflammatory func-
tion [148]. Further evidence of the immunological interactions of
VEGFR1 come from a an antibody-independent mouse model of spon-
taneous miscarriage and intrauterine growth restriction (IUGR), where
an increase in complement activation resulted in increased levels of
circulating VEGRF1 [149]. It was also confirmed that monocytes can be
stimulated to express an excess of VEGFR1, when exposed to the ana-
phylatoxic complement activation products C3a and C5a in vitro [149].
Furthermore, complement activation, i.e. C3a causes upregulation of
Flt1 by the syncytiotrophoblast. Release of the overexpressed sFlt1 re-
quired activation of the TP [150] and complement activation is corre-
lated with sFlt1 expression [151]. Also macrophage polarization to
proinflammatory M1 and tolerogenic M2 is possibly driven by the
VEGF-signaling pathway, which is dysregulated in preeclampsia [152].
Genetic association of the FLT1 gene, which encodes Flt1, with both
fetal and maternal susceptibility to preeclampsia was recently con-
firmed [153,154]. It seems possible that in preeclampsia, the excess of
sFlt1 and inflammatory stimuli are linked to each other, but the exact
causality and dynamics of the complex interactions are still unclear.
6. Complement-mediated clearance of free fetal DNA
The maternal-fetal interface undergoes a major reconstruction
during the placental development. It follows that there also has to be a
considerable amount of apoptosis and cell necrosis going on.
Furthermore, a significant number of particles will be shed into the
maternal circulation from the placental syncytiotrophoblast from the
very early stages of pregnancy onwards [155].
The preeclamptic pregnancy results in an increased load of apop-
totic cells and sub-cellular debris into the maternal circulation [156].
An increased load of free-floating DNA is observed in the maternal
plasma of preeclamptic women prior to the onset of the disease [157].
Extracellular fetal DNA has a proinflammatory effect, which has been
linked to an adverse pregnancy outcome [158]. The C4BP is a soluble
regulator of the CP that binds to chromatin and facilitates clearance of
the fetal free-floating DNA from the maternal circulation in an anti-
inflammatory fashion [159]. Mutations in the gene coding for C4BP
have been linked with recurrent pregnancy loss [41]. Furthermore,
deposition of C4d and C4BP in the sub-endothelial layer of the glo-
merular capillary walls in a preeclamptic patient suggests a role for
complement activation in the endothelial dysfunction that is char-
acteristic to the disease [55].
CR3 and CR4 have been observed to recognize certain danger-as-
sociated signals, like HMGB1 and extracellular DNA in a process that
likely has clinical consequences in promoting chronic inflammation
[160,161]. CR2 on B-cells and follicular DCs also binds free-floating
DNA leading to a possible humoral immune response against the free-
floating fetal DNA [124]. However, the proportion of fetal to maternal
DNA in the maternal plasma is very low. Therefore the pathological role
of increased fetal DNA load as observed in preeclampsia is unclear.
7. Tolerance in pregnancy
The fetus and placenta together constitute a genetic allograft
nourished by the maternal circulation. In a healthy pregnancy, an im-
munosuppressed balance persists throughout the pregnancy. In addition
to being efficiently controlled itself, the complement system may also
act directly or indirectly to establish and maintain tolerance during
pregnancy. The complement system plays an important part in helping
adaptive immune responses. In a murine pregnancy model, an inter-
action of complement receptor 3 (CR3) with iC3b at the maternal-fetal
interface results in the induction of local anti-inflammatory cytokine
expression. Furthermore, in late murine pregnancy, iC3b has a role in
promoting production of the anti-inflammatory cytokines IL-10 and
TGF-β1 [162]. Typically, complement removes endogenous waste
products with the help of iC3b, which has been rapidly generated from
C3b on host cell structures. Cells containing receptors mediating intake
of iC3b coated particles, are typically capable of producing the im-
munosuppressive cytokines IL-10 and TGF-β1. IL-10 is known to sup-
press T–cell activation by preventing proinflammatory cytokine pro-
duction and up-regulation of molecules involved in antigen
presentation by DCs and macrophages [163] TGF-β1 has an important
role in preventing T-cell activation by self-antigens [164]. In addition,
the deposition of C3dg and C3d on antigens is an important means of
antigen uptake to antigen presenting cells, such as DCs, follicular DCs, B
cells, and macrophages, and further in their delivery to the adaptive
lymphatic system [165]. The role of complement in orchestrating
adaptive immune responses is relatively well understood. However, in
the context of human pregnancy, the extent to which the complement
system orchestrates the adaptive immune response and the develop-
ment of tolerance remains largely unexplored.
There are several well-known mechanisms at the fetomaternal in-
terface guarding the well-being of the fetus (Fig. 2). The placenta is
protected by a syncytium layer of fused trophoblast cells. Complement
inhibitors have been shown to be strongly expressed by cells in the
placenta and in the outer layer of the syncytium [45,166]. While the
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placental trophoblast cells do not express the classical major histo-
compatibility complex (MHC) molecules, the tolerogenic HLA-G, HLA-
F, and HLA-E, all with unremarkable polymorphism, are expressed by
the extra-villous trophoblast. HLA-G expression on the extra-villous
trophoblast protects the placenta from cytotoxic reactions. Low soluble
HLA-G plasma levels have been linked to severe preeclampsia [167].
During placentation, the invasive extra-villous trophoblast cells express
HLA-C receptors that interact with the KIR-receptors of the uterine
natural killer cells to establish an anti-inflammatory, immunotolerant
maternal response to the fetus in the healthy pregnancy [168–172].
Uterine NK cells have been shown to be less cytotoxic, when compared
with their peripheral blood counterparts [173,174]. They are essential
in the placental development and in the encounter with invading extra-
villous trophoblast cells. Despite efforts not to express polymorphic
HLA molecules on the surface of the placenta, the syncytium contains
intracellular HLA-DR molecules [175]. The reason for this is not known.
Regulatory T cells (Tregs) have been shown to be essential in the
very early stages of pregnancy [175]. Paternal antigen-specific Tregs
are considered to be induced already before pregnancy through ex-
posure to semen, which contains paternal antigens and TGF-β [4]. TGF-
β is important in Treg induction. On the maternal side, the decidual
macrophages are predominantly of the anti-inflammatory type (M2)
[176]. Healthy pregnancy is characterized by an early M2 polarization
of the decidua, while M1-dominated pregnancies are associated with
spontaneous abortions [177]. C1q is upregulated in macrophages by
anti-inflammatory cytokines, suggesting a possible tolerance-inducing
role for the complement-macrophage interaction in the maternal-fetal
interface [178]. This would be logical for the proposed role of macro-
phages in removing placental debris with the help of C1q in a nonin-
flammatory fashion. Indeed, a clear decrease in the serum level of C1q
in preeclamptic patients has been observed, likely due to depletion of
C1q in heavy demand [179]. In preeclampsia, increases in the levels of
pro-inflammatory cytokines tumor necrosis factor alpha (TNF-α) and
IL-6 have been recorded [180]. A shift towards the inflammatory Th1-
type reactivity, instead of the noninflammatory Th2 reactivity, is a
known phenomenon in preeclampsia [181]. Possibly in a compensatory
attempt, increased plasma levels of immunosuppressive IL-10 have
been reported in the third trimester of preeclamptic pregnancies [180].
Additionally, indoleamine 2,3-dioxygenase (IDO) is present and an
important part of the tolerance mechanism in the fetomaternal interface
[182]. T cell activation in the IDO environment induces anergic and
regulatory T cells. While the exact interaction between IDO and com-
plement system is not known, murine studies have shown that the in-
hibition of IDO unleashes local complement activation and promotes
inflammation with possible clinical consequences [183].
8. Conclusions
Pregnancy brings about tremendous changes in the body fluid vo-
lume and distribution. Fundamentally, preeclampsia is a disease that
reflects an underlying failure in regulating vascular and hemodynamic
changes in pregnancy. This may be due to a dysregulation of im-
munological processes and the subsequent loss of tolerance to the al-
logenic fetoplacental unit. This process would be analogous to that seen
in autoimmunity and SLE [184]. As the woman is exposed to a ge-
netically foreign fetus during pregnancy, there could be an intentional
reason for the enormous load of placental shedding that occurs [185].
Apoptotic bodies are ingested by macrophages and DCs, and the en-
vironment and receptors included in the process determine whether
tolerance or an immunoinflammatory process is initiated. In a healthy
pregnancy, clearance of the apoptotic cells of fetal origin may serve to
induce a tolerogenic response, while in a preeclamptic pregnancy, the
response could be inflammatory. It is therefore conceivable that the
pregnant woman’s ability to process the released material from placenta
contributes to the risk of the pregnancy complications and compro-
mised endothelial integrity with possible consequences for vascular
health in later life. The complement system likely acts as a mediator
and regulator of the key processes in the pathogenesis of preeclampsia
including breach of tolerance, inflammation, and waste management.
The emerging noncanonical roles for the complement system have the
potential to improve the understanding of the role of complement re-
ceptors and regulators as guard keepers in healthy and preeclamptic
pregnancy.
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